Biopharmaceutical company developing products for the treatment of ear-related conditions.
Fennec Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of innovative therapies. At the forefront of its clinical pipeline is PEDMARK, a formulation of sodium thiosulfate designed to prevent platinum-induced ototoxicity in pediatric cancer patients. This product candidate addresses a critical need in pediatric oncology by mitigating the debilitating side effects associated with platinum-based chemotherapy.
Originally known as Adherex Technologies Inc., the company rebranded as Fennec Pharmaceuticals Inc. in September 2014 to reflect its focused commitment to advancing novel treatments for pediatric cancers. Founded in 1996 and headquartered in Research Triangle Park, North Carolina, Fennec Pharmaceuticals has established itself as a dedicated player in the biopharmaceutical industry.
Fennec Pharmaceuticals leverages its scientific expertise and strategic partnerships to drive the development and commercialization of PEDMARK. The company's efforts are guided by a mission to improve outcomes and quality of life for pediatric cancer patients undergoing chemotherapy. By addressing unmet medical needs with innovative solutions, Fennec Pharmaceuticals aims to make a meaningful impact in the field of pediatric oncology.
With a strong emphasis on research and development, Fennec Pharmaceuticals continues to expand its pipeline and explore new therapeutic avenues. The company remains committed to advancing PEDMARK through clinical trials and regulatory approval processes, with the goal of providing a much-needed therapy to pediatric patients worldwide.